Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator‐mandated cohort postauthorization safety study in Denmark, Norway, and Sweden-Reference-Cited by-同舟云学术

Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator‐mandated cohort postauthorization safety study in Denmark, Norway, and Sweden

Published:2021-07-26 Issue:21 Volume:127 Page:4050-4058
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ehrenstein Vera¹^ORCID,Heide‐Jørgensen Uffe¹,Schiødt Morten²^ORCID,Akre Olof³^ORCID,Herlofson Bente Brokstad⁴⁵^ORCID,Hansen Svein⁶,Larsson Wexell Cecilia⁷⁸^ORCID,Nørholt Sven Erik⁹¹⁰^ORCID,Tretli Steinar⁶^ORCID,Kjellman Anders³^ORCID,Glennane Anthony¹¹,Lowe Kimberly A.¹²^ORCID,Sørensen Henrik T.¹^ORCID

Affiliation:

1. Department of Clinical Epidemiology Aarhus University Hospital, Institute of Clinical Medicine, Aarhus University Aarhus Denmark

2. Department of Oral and Maxillofacial Surgery Rigshospitalet Copenhagen Denmark

3. Urology Department Karolinska University Hospital Stockholm Sweden

4. Department of Oral Surgery and Oral Medicine Faculty of Dentistry University of Oslo Oslo Norway

5. Division for Head, Neck and Reconstructive Surgery, Department of Otorhinolaryngology–Head and Neck Surgery Oslo University Hospital Oslo Norway

6. Department of Research Cancer Registry of Norway Oslo Norway

7. Department of Oral and Maxillofacial Surgery Skåne University Hospital Lund Sweden

8. Department of Biomaterials Sahlgrenska AcademyUniversity of Gothenburg Göteborg Sweden

9. Department of Oral and Maxillofacial Surgery Aarhus University Hospital Aarhus Denmark

10. Department of Dentistry and Oral Health Aarhus University Aarhus Denmark

11. Clinical Development, Amgen, Inc Thousand Oaks California

12. Center for Observational Research Amgen, Inc Thousand Oaks California

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33802

Reference28 articles.

1. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

2. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

3. Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases;Lung Cancer;2024-07

2. Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management;Scientific Reports;2024-06-11

3. Oral manifestations of systemic disorders – part 2;Den norske tannlegeforenings Tidende;2024-02-15

4. Cinobufotalin Capsule Combined with Zoledronic Acid in the Treatment of Pain Symptoms and Clinical Efficacy in Prostate Cancer Patients with Bone Metastases: A Retrospective Study;Archivos Españoles de Urología;2024

5. Pre-existing medication-related osteonecrosis of the jaw before dental extraction;British Dental Journal;2023-11-24